In the Philippines, immuno-oncology is approved by the Food and Drug Administration as treatment option for nonsmall cell lung cancer
, Hodgkin lymphoma, melanoma, head and neck, bladder, and gastric cancers.
Differential expression and activation of epidermal growth factor receptor 1 (EGFRI), ERK, AKT STAT3, and TWIST 1 in nonsmall cell lung cancer
Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer
. Cancer 2012;118:1726-1737.
Survival in early-stage nonsmall cell lung cancer
. The Annals of Thoracic Surgery.; 60: 466-472 (1995).
Grape seed proanthocyanidins inhibit the growth of human nonsmall cell lung cancer
xenografs by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors.
Introduction: Nonsmall cell lung cancer
(NSCLC) is the leading cause of cancer-related deaths in many countries.
Blockade of pathways involving PD-1 and its ligand is a promising treatment for cancers (melanoma, nonsmall cell lung cancer
, metastatic renal cell carcinoma, head and neck carcinomas, Hodgkin lymphoma, and urothelial carcinoma) (4), although the role of PD1/programmed death ligand 1 in immune suppression and the mechanism of action of antibodies remain to be better defined.
Human immunodeficiency virus infection and nonsmall cell lung cancer
: survival and toxicity of antineoplastic chemotherapy in a cohort study.
A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer
. Nucl Med Commun 2010;31:646-651.
The Company received the FDA's approval to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibody in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and nonsmall cell lung cancer
Evaluation of three small molecular drugs for targeted therapy to treat nonsmall cell lung cancer
. Chin Med J 2016;129:332-40.
In a separate study, also published in Science, investigators led by Bertrand Routy, MD, of the Gustave Roussy Cancer Institute in Villejuif, France, reported that patients with nonsmall cell lung cancer
and urothelial carcinoma who had previously used systemic antibiotics had reduced survival when treated with a PD-1 inhibitor, compared with patients who had never taken antibiotics (Science.